Barton Haynes

Last updated

Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012. [1] In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006. [2] [3]

Haynes was the director of the Center for HIV/AIDS Vaccine Immunology (CHAVI), which was funded by the NIAID from 2005 to 2011 to overcome obstacles to HIV vaccine development. [4] [5] The "big science" approach of the CHAVI grant enabled the following scientific discoveries by the CHAVI team: 1) the delineation of HIV-1 transmitted/founder viruses that are responsible for the transmission of HIV/AIDS; 2) the discovery of host tolerance mechanisms that limit the induction of broad neutralizing antibodies in HIV-1 infection; 3) the fine mapping and delineation of the immunological events that transpire during the earliest days of HIV-1 infection; 4) the discovery of new genes and gene mutations/duplications that contribute to HIV-1 control and progression; 5) the design of mosaic T cell and B cell Env vaccine candidates to overcome HIV diversity; 6) the discovery of the immune correlates of risk of infection in the RV144 trial; [6] 7) the isolation of rare broad neutralizing HIV antibodies and their ancestor antibodies; and 8) the development of a new strategy for vaccine development called B Cell Lineage Immunogen Design. [7] [8] He led the group that deciphered the maturation pathways of several types of broadly neutralizing antibodies that point the way to vaccine designs, and has worked out the immunobiology of HIV-host interactions that control broad neutralizing antibody development. [9] [10] [11]

Haynes received his bachelor's degree from the University of Tennessee in 1969 and his M.D. from Baylor College of Medicine in 1973. He completed his internship and residency at Duke University Medical Center in 1975. After conducting research for five years at the National Institute of Allergy and Infectious Diseases from 1975 to 1980, Haynes returned to Duke as a member of the faculty in the department of medicine in 1980. [12] He served as Chief of the Division of Rheumatology, Allergy and Clinical Immunology from 1987 to 1995, and as chair of the department of medicine from 1995 to 2002 at Duke University Medical Center. Haynes established the Duke Human Vaccine Institute in 1990 to support interdisciplinary efforts across Duke to develop vaccines and therapeutics for HIV and other emerging infections. [13] [14]

Haynes served as a member of the NIAID Advisory Council, [15] Chairman of the National Academy of Sciences Institute of Medicine Roundtable for Development for Drugs and Vaccines against AIDS, and currently is chair of the NIAID AIDS Vaccine Research Working Group that advises the National Institutes of Health (NIH) regarding the national HIV vaccine effort. Haynes served on the NIAID Blue Ribbon Committees on Bioterrorism and Emerging Infections held in February and October 2002. He received the Alexander Fleming Award for Lifetime Achievement from the Infectious Diseases Society of America in 2011 and the Ralph Steinman Award for Human Immunology Research from the American Association of Immunologists in 2013. [16] [17] He was the recipient of the Duke Award for Basic Science Mentoring in 2011. Haynes is a Fellow of the Infectious Diseases Society of America and is a member of the Association of American Physicians, the National Academy of Sciences Institute of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. [18]

Related Research Articles

<span class="mw-page-title-main">HIV vaccine development</span> In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals.

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

This is a list of AIDS-related topics, many of which were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

Long-term nonprogressors (LTNPs), sometimes also called elite controllers, are individuals infected with HIV, who maintain a CD4 count greater than 500 without antiretroviral therapy with a detectable viral load. Many of these patients have been HIV positive for 30 years without progressing to the point of needing to take medication in order not to develop AIDS. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to the development of immune therapies or a therapeutic vaccine. The classification "Long-term non-progressor" is not permanent, because some patients in this category have gone on to develop AIDS.

<span class="mw-page-title-main">La Jolla Institute for Immunology</span>

La Jolla Institute for Immunology is a non-profit research organization located in La Jolla, California. It is located in UC San Diego’s Research Park. The institute researches immunology and immune system diseases. The institute employs 220 M.D.s and Ph.D.s, including 23 faculty members and more than 450 employees. Dr. Mitchell Kronenberg has served as its president and scientific director since 2003. The institute was founded in 1988.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

HVTN 505 is a clinical trial testing an HIV vaccine regimen on research participants. The trial is conducted by the HIV Vaccine Trials Network and sponsored by the National Institute of Allergy and Infectious Diseases. Vaccinations were stopped in April 2013 due to initial results showing that the vaccine was ineffective in preventing HIV infections and lowering viral load among those participants who had become infected with HIV. All study participants will continue to be monitored for safety and any long-term effects.

<span class="mw-page-title-main">Stephen C. Harrison</span> American chemist and pharmacologist

Stephen C. Harrison is professor of biological chemistry and molecular pharmacology, professor of pediatrics, and director of the Center for Molecular and Cellular Dynamics of Harvard Medical School, head of the Laboratory of Molecular Medicine at Boston Children's Hospital, and investigator of the Howard Hughes Medical Institute.

In 1990, the Duke Human Vaccine Institute (DHVI), located in Durham, North Carolina, was formed to support interdisciplinary efforts across Duke University School of Medicine to develop vaccines and therapeutics for HIV and other emerging infections that threaten the health of people living in the United States and the world. Since 1990, DHVI investigators have been at the forefront in the battle against AIDS and specifically in the quest for an HIV vaccine.

<span class="mw-page-title-main">William E. Paul</span> American immunologist

William Erwin Paul was an American immunologist. He and Maureen Howard discovered interleukin 4, while an independent team led by Ellen Vitetta did the same in 1982. Paul worked on AIDS research for much of his career at the National Institutes of Health (NIH). He served as president of the American Association of Immunologists from 1986 to 1987.

<span class="mw-page-title-main">Lauren V. Wood</span> American allergist, immunologist

Lauren V. Wood is an American allergist, immunologist, and staff physician at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. She is known for conducting studies of vaccines for cancer, Human papillomavirus (HPV), Hepatitis C, and HIV especially for use with children, teens and young adults. She holds the rank of captain in the U.S. Public Health Service (PHS).

M. Juliana “Julie” McElrath is a senior vice president and director of the vaccine and infectious disease division at Fred Hutchinson Cancer Research Center and principal investigator of the HIV Vaccine Trials Network Laboratory Center in Seattle, Washington. She also is a professor at the University of Washington.

Gary J. Nabel is an American virologist and immunologist, and President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts.

<span class="mw-page-title-main">Susan Zolla-Pazner</span> American research scientist

Susan Zolla-Pazner is an American research scientist who is a Professor of Medicine in the Division of Infectious Diseases and the Department of Microbiology at Mount Sinai School of Medicine and a guest investigator in the Laboratory of Molecular Immunology at The Rockefeller University, both in New York City. Zolla-Pazner's work has focused on how the immune system responds to the human immunodeficiency virus (HIV) and, in particular, how antibodies against the viral envelope develop in the course of infection.

<span class="mw-page-title-main">Nancy Sullivan (biologist)</span> American cell biologist

Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.

<span class="mw-page-title-main">Nicole Doria-Rose</span> American biologist

Nicole Amy Doria-Rose (born 1970) is an American biologist. She is chief of the humoral immunology core at the Vaccine Research Center. She develops and applies assays to evaluate HIV-1 specific antibody responses during natural infection and after immunization.

Catherine Blish is a translational immunologist and professor at Stanford University. Her lab works on clinical immunology and focuses primarily on the role of the innate immune system in fighting infectious diseases like HIV, dengue fever, and influenza. Her immune cell biology work characterizes the biology and action of Natural Killer (NK) cells and macrophages.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs.

References

  1. ↑ National Institutes of Health." NIH Awards $31 Million for HIV/AIDS Vaccine Immunology and Immunogen Discovery." Press Release. July 11, 2012.
  2. ↑ Cohen, Jon (2006). "Gates Foundation Doubles Support for AIDS Vaccine Research". Science. 313 (5785): 283. doi:10.1126/science.313.5785.283a. PMID   16857908. S2CID   6506698.
  3. ↑ Collaboration for AIDS Vaccine Discovery. About the Grantees.
  4. ↑ National Institutes of Health. "NIAID Funds Center for HIV/AIDS Vaccine Immunology (CHAVI) Archived August 2, 2009, at the Wayback Machine ." Press Release. July 14, 2005.
  5. ↑ National Institute of Allergy and Infectious Diseases. Center for HIV/AIDS Vaccine Immunology. Questions and Answers Archived August 30, 2009, at the Wayback Machine .
  6. ↑ Haynes, BF; Gilbert, PB; McElrath, MJ; Zolla-Pazner, S; Tomaras, GD; Alam, SM; Evans, DT; Montefiori, DC; Karnasuta, C; Sutthent, R; et al. (2012). "Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial". N. Engl. J. Med. 366 (14): 1275–86. doi:10.1056/NEJMoa1113425. PMC   3371689 . PMID   22475592.
  7. ↑ Haynes, BF; Kelsoe, G; Harrison, SC; Kepler, TB (2012). "B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study". Nat. Biotechnol. 30 (5): 423–33. doi:10.1038/nbt.2197. PMC   3512202 . PMID   22565972.
  8. ↑ Center for HIV/AIDS Vaccine Immunology. Progress Reports Archived August 25, 2013, at the Wayback Machine .
  9. ↑ Bonsignori, Mattia (March 2, 2016). "Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody". Cell. 165 (2): 449–63. doi:10.1016/j.cell.2016.02.022. PMC   4826291 . PMID   26949186.
  10. ↑ Haynes, Barton (March 9, 2016). "HIV-Host Interactions: Implications for Vaccine Design". Cell Host Microbe. 19 (3): 292–303. doi:10.1016/j.chom.2016.02.002. PMC   4823811 . PMID   26922989.
  11. ↑ Verkoczy, Laurent (May 9, 2014). "AIDS/HIV. Host controls of HIV neutralizing antibodies". Science. 344 (6184): 588–589. doi:10.1126/science.1254990. PMC   4162091 . PMID   24812389.
  12. ↑ Simon Noble. "An Interview with Barton Haynes: A new virtual Center Archived June 4, 2011, at the Wayback Machine ." IAVI Report. 2005 Sep/Oct 9(4);4
  13. ↑ Duke Human Vaccine Institute. About the Institute Archived March 4, 2011, at Archive-It .
  14. ↑ UNC-TV. The New Age of HIV/AIDS. Interview: Bart Haynes, M.D. Archived April 6, 2009, at the Wayback Machine
  15. ↑ James Hadley. "HHS Secretary Names Five to NIAID Advisory Council Archived August 30, 2009, at the Wayback Machine ." National Institute of Allergy and Infectious Diseases. Feb. 26, 1999
  16. ↑ Infectious Diseases Society of America. Alexander Fleming Award Winners Archived 2012-07-23 at the Wayback Machine .
  17. ↑ American Association of Immunologists. 2013 AAI Award Recipients Archived 2013-03-20 at the Wayback Machine .
  18. ↑ Duke University Medical Center Office of Publications. "Haynes Elected to Academy." Inside DUMC 2002-09: May 07, 2007 Volume 16 No. 9
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.